Featured Products
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for glycemic control and metabolic management under physician supervision. It works by mimicking endogenous GLP-1 to enhance insulin secretion, reduce glucagon levels, slow gastric emptying, and promote satiety.
Semaglutide is used in regulated medical settings as part of comprehensive treatment protocols for metabolic health. It must be prescribed and administered in accordance with applicable regulatory guidelines.
Retatrutide is an investigational multi-receptor agonist peptide designed to target metabolic signaling pathways. It acts on GLP-1, GIP, and glucagon receptors, making it part of a newer class of triple-hormone receptor agonists under clinical development for metabolic research.
Unlike single-pathway agents, retatrutide is engineered to influence multiple mechanisms involved in glucose regulation, appetite signaling, and energy expenditure.
Tirzepatide is a synthetic dual incretin receptor agonist that targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It is designed to support metabolic regulation through multiple hormonal pathways involved in insulin secretion, glucose control, and appetite signaling.
By activating both receptors, tirzepatide represents a dual-mechanism approach within the incretin-based therapeutic class.
Our Services
Inquire about our Wholesale account?